Halozyme has acquired Surf Bio for an upfront payment of $300 million, subject to customary purchase price adjustments, and up to $100 million milestone payments based on product development and regulatory approval milestones, for a total consideration of up to $400 million. Launched in 2021 by the founders of Bigfoot Biomedical and Mode AGC, Surf Bio is a preclinical biopharmaceutical company that develops drug delivery technologies to transform how antibodies and biologics are delivered to ...